Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends

Apr 15 2016

• By Sue Sutter

Related Content

Serono Infertility Treatment Luveris Clears FDA

Oct 25 2004

Serono Luveris Data Support Follicular Development Indication, Cmte. Says

Oct 06 2003

FDA Infertility Trial Endpoints: Committee Says Don’t Count Your Eggs

Oct 06 2003

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 21 2011

AstraZeneca’s <em>Iressa</em>, Now Resurrected, Faces Daunting U.S. EGFR Market

Jul 20 2015

Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Dec 20 2010

The ABCs Of Accelerated Approval Withdrawals

Oct 28 2013

Related Companies

Merck KGaA

Merck KGaA

Genentech, Inc.

AstraZeneca PLC

Additional Topics

United States Regulation Post Market Regulation & Studies BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window